INS and hydrops fetalis: The ORIGIN (Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia) trial was the only major study with an insulin-only treatment arm that evaluated CV outcomes with basal insulin therapy versus standard regimen in 12,537 patients with impaired glycemic control and at high risk for adverse CV events.19 No significant difference in the coprimary outcome of CV death, nonfatal myocardial infarction, nonfatal stroke, revascularization procedures, and HF hospitalizations was observed with insulin therapy compared with standard of care (28.6% vs 27.5%; HR, 1.04; 95% CI, 0.97-1.11).